Key facts
- It has raised $51.7M; the latest was PE Growth/Expansion ($51.7M) in Jan 2025.
- Notable investors include Lauxera Capital Partners, S-Kap Unternehmensbeteiligungs.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Acandis
- ·The full record, as it builds
Funding rounds
No funding rounds for Acandis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Acandis
Manufacturer of medical devices intended to help in the treatment of neurovascular diseases. The company specializes in manufacturing of products with a comprehensive understanding of symptoms, diagnostics and treatment options to detailed analysis of technical viability, enabling neuroradiologists to tackle technical and medical challenges with effective and user-oriented devices along with helping maintain and improve the quality of life of people.
- Sector
- Healthcare
- HQ
- Pforzheim, Germany
- Founded
- 2006
- Employees
- 300
- Website
- acandis.com/
- Ownership
- Privately Held (backing)
Acandis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Acandis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Acandis in its N-PORT filings yet. We sweep new filings monthly.